Clinical Trial

MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 14, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.
Trial Details
NCT Number NCT06170294
Lead Sponsor Peking University
Collaborators: Shanghai Ming Ju Biotechnology Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 20 participants
Start Date 2024-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-12-14